Skip to main content
. Author manuscript; available in PMC: 2015 May 13.
Published in final edited form as: Nat Commun. 2015 Apr 2;6:6411. doi: 10.1038/ncomms7411

Figure 2. Deregulation of the Hippo pathway in osteosarcomas.

Figure 2

(a) Western analysis of YAP, Nf2 and WWC1 in murine and human osteosarcoma cell lines. (b) YAP and Sox2 expression in a spontaneous osteosarcoma in a bone-specific p53/Rb-knockout mouse. Massie's trichrome stain (left panel) and immunohistochemistry with Sox2 (middle panel) and YAP (right panel) antibodies demonstrate that differentiated areas of the tumour (stained blue for collagen) have low expression of Sox2 and YAP. Scale bar, 100 μm. (c) mRNA expression of YAP, Nf2 and WWC1 in human osteosarcomas tumour samples. Box plot shows mRNA expression of YAP, Nf2 and WWC1, as compared with control (red line). A=chondroblastic osteosarcoma; B =fibroblastic osteosarcoma; C=osteoblastic osteosarcoma; and D=telangietactic osteosarcoma. Data used in this analysis were downloaded from www.oncomine.org. (d) Expression of the 8X-GTIIC(TEAD) luciferase reporter in mOS-482 cells expressing either scrambled or two independent Sox2 shRNAs -A and B. Cells were transfected with a TEAD-Luciferase (Firefly) reporter. Luciferase activity was normalized to Renilla luciferase. *P<0.05 by ANOVA. Error bars represent mean ± s.d. (e) Western analysis of phospho- and total YAP in mOS-482 cells expressing scrambled or two independent Sox2 shRNAs-A and B. The anti-phospho YAP antibody recognizes the phosphorylated S127 residue.